Skip To Main Content
Marc-Oliver Grimm on Muck Rack

Marc-Oliver Grimm

As seen in: Nature, Wiley Online Library, ScienceDirect, MDPI, JAMA Oncology, The Lancet, Future Medicine, OncLive, European Urology, UroToday
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Marc-Oliver

Contact Marc-Oliver, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Perioperative Treatment with Durvalumab in Combination with Neoadjuvant Chemotherapy in Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer.

|
By Marco Schnabel, Marc-Oliver Grimm, Peter J Goebell
| UroToday Verified
Since July 2025, perioperative durvalumab combined with neoadjuvant gemcitabine/cisplatin chemotherapy followed by radical cystectomy has been approved in Germany for the treatment of muscle-invasive bladder cancer. This approval was based on the phase III NIAGARA trial, which demonstrated that the combination led to a significant improvement in event-free survival compared with neoadjuvant chemotherapy alone.
Open in Who Shared Issue with article?

Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma After Prior Therapy: Final Results from the Non-Interventional NORA Study.

|
By Marc-Oliver Grimm, Viktor Grünwald, Harald Müller-Huesmann
| UroToday Verified
Background/Objectives: Nivolumab monotherapy is a standard of care in previously treated advanced renal cell carcinoma (aRCC) and was approved based on the results of the randomized clinical trial Checkmate-025. The non-interventional study (NIS) NORA collected data on the effectiveness and safety of nivolumab monotherapy in real-world clinical routine. Its final, long-term follow-up data are presented here.
Open in Who Shared Issue with article?

Differential effects of prior versus concomitant Steroid and Antibiotic Treatment on Immunotherapy Efficacy - A Pooled Analysis of the RAMONA, INTEGA, OPTIM, ELDORANDO, FORCE, TITAN-RCC and TITAN-TCC Trials of the German AIO Study Group

|
By Isabella C. Wiest, Lena Dreikhausen, Laurence Albigès, Katharina Leucht, Stefan Rieken, Emilio Esteban, Friedemann Zengerling, Joseph Tintelnot, Marc-Oliver Grimm, Farastuk Bozorgmehr, Petros Christopoulos, Alexander Stein, Mascha Binder, Nicolai Härtel, Konrad Klinghammer, Viktor Grünwald, Michael Pogorzelski, Matthias Ebert, Ralph Keller, Marcos Marin-Galiano, Johannes Meran
| Nature Verified
Abstract We explored the association of immune-related adverse events (irAE), along with prior and concomitant antibiotic and steroid use, on oncological outcomes following immune checkpoint inhibitor (ICI) treatment in various solid tumours.
Open in Who Shared Issue with article?
See all 22 licensed articles (25 Total)